By Daniel Park, MS, Health Content Specialist. Medically reviewed by Dr. Anika Rao, MD, Board-Certified Internal Medicine.
Last March, a woman named Christine in suburban Denver spent an entire Saturday morning with two browser tabs open: Hims on the left, Henry Meds on the right. She'd been quoted $199 to start at Hims and $399 at Henry Meds. "The Hims number looked like a no-brainer," she told me. "Then I priced out what I'd actually pay at 10 mg six months in, and the math flipped completely." She ended up choosing Henry Meds, stayed for nine months, and says she would have wasted hundreds if she'd only looked at the month-one sticker.
Christine's spreadsheet moment is playing out across thousands of kitchen tables right now. Both Henry Meds and Hims are massive, licensed telehealth platforms with national reach and compounded tirzepatide programs. On the surface they look interchangeable. Underneath, they're built on fundamentally different logic, and the right pick depends almost entirely on how long you plan to use the medication and how much clinical contact you actually want.
This article is part of the FormBlends best tirzepatide telehealth providers comparison and the compounded tirzepatide complete guide.
The one thing that separates them
Strip away the branding and you're looking at two different business architectures.
Hims is an efficiency machine. Async intake, aggressive starter pricing, multi-month prepay discounts, minimal clinical friction. It's optimized to get a healthy person from "interested" to "medication shipped" as fast as possible. The clinical layer is real (state-licensed clinicians do chart review) but deliberately light. Think of it like booking a flight on a discount carrier: the plane gets you there, the seat is fine, but nobody's checking on you mid-flight.
Henry Meds is built around a different bet. Live video visits are part of the standard program. Pricing is flat across all doses, meaning a patient on 12.5 mg pays the same monthly fee as a patient on 2.5 mg. The onboarding is slower, the sticker price at month one is higher, and the whole thing feels more like a clinic that happens to be online.
Here's the thing: neither model is wrong. They serve different patients. But the marketing on both sides buries the structural gap under identical-sounding promises, and that's where people get tripped up.
What the numbers actually look like
These are approximate 2026 figures. Verify current pricing on each provider's site before committing.
Hims compounded tirzepatide:
- Month 1 (2.5 mg starter): around $199
- Months 2-3 (5 mg): around $279 to $349
- Maintenance doses (7.5 mg, 10 mg, 12.5 mg, 15 mg): meaningfully higher, with multi-month plans available to bring the per-month cost down
Henry Meds compounded tirzepatide:
- Monthly plan: around $399 per month, flat across doses
- 3-month prepaid plan: around $349 per month
- 6-month prepaid plan: around $297 per month
The crossover is straightforward arithmetic. A patient who tries tirzepatide for two or three months at the starter dose and stops? Hims is cheaper, no contest. A patient who escalates to 10 mg and stays for a year? Henry Meds almost certainly wins on total cost. The exact breakeven depends on current promotional pricing and which dose you settle on, but the pattern holds.
Two very different ideas about clinical care
Hims:
Not sure which GLP-1 is right for you?
Take a 2-minute assessment and get a personalized recommendation after licensed provider review.
Take the Assessment →- Async medical intake questionnaire
- Clinician chart review (state-licensed)
- No live video visit required for most patients
- Async messaging for ongoing questions
- Dose escalation managed through the patient portal
Henry Meds:
- Online intake plus live video visit (optional or required depending on plan)
- Same state-licensure standards
- Patient-initiated live video visits throughout the program
- Async messaging plus live access
- Dose escalation reviewed by a clinician on a visit or via message
For a healthy 35-year-old with a BMI of 32 and no other medical history, async intake is perfectly reasonable. For someone managing type 2 diabetes, a history of pancreatitis, or thyroid concerns, the Henry Meds model with its live-access clinician is the more conservative, and probably smarter, choice.
My honest opinion: the industry as a whole underweights clinical contact. GLP-1 dose escalation isn't dangerous for most people, but "not dangerous" and "optimally managed" are not the same sentence.
Where the medication actually comes from
Neither platform publishes its full list of compounding pharmacy partners on the main marketing page. Both work with state-licensed 503A compounding pharmacies. Both identify the dispensing pharmacy on the medication label.
Hims, because of its scale, uses a larger portfolio of pharmacy partners. The specific pharmacy filling your order can vary by state and over time. Henry Meds has historically used a smaller set of partners, though that's been changing as the platform grows.
Certificates of analysis are available on request from both platforms but aren't provided automatically in the order flow. You have to ask. Most patients don't.
The branded Zepbound question
This is a meaningful differentiator. Hims offers both compounded tirzepatide and branded Zepbound through Lilly's direct programs. If your insurance covers Zepbound, you can use Hims's clinical front-end and route the prescription through traditional pharmacy channels, potentially paying far less than any compounded option.
Henry Meds is primarily compounded-focused. Branded Zepbound is not a core part of their offering.
For the roughly 15-20% of patients whose employer-sponsored plans actually cover obesity medicine, Hims's branded pathway is worth investigating first. For the majority without coverage, both platforms compete on compounded pricing alone.
Regulatory heat on both sides
Both platforms operate in the same regulatory environment, and both have drawn public scrutiny during the compounded GLP-1 enforcement wave of 2024 and 2025.
Hims: The company's high-profile Super Bowl LIX ad in February 2025 promoting compounded GLP-1s prompted letters from U.S. senators to the FDA. Broader trade-press coverage has scrutinized the company's marketing practices around compounded medications.
Henry Meds: Named in some of Eli Lilly's trademark and false-advertising litigation against compounded GLP-1 marketers in 2024 and 2025. The FDA warning letter database is public and searchable directly.
Neither platform is operating illegally as of early 2026. But the regulatory landscape is shifting fast, and prospective patients should check current status before enrolling. Public records are available on PACER and the FDA warning letter database.
State coverage and shipping
Both platforms ship to most U.S. states with periodic state-specific limitations driven by changing compounding regulations. California, Florida, Mississippi, and a few other states have had restrictions at various times. Always verify shipping to your state at checkout. This is one of those details that changes quarterly and frustrates everyone.
What's included (and what isn't)
Both platforms include medication, clinician review, syringes and supplies, and patient portal access. Neither includes structured coaching, dietitian access, or lab monitoring as part of the standard program. If those matter to you, platforms like Mochi Health and Lavender Sky Health are designed differently.
What patients actually say
Both platforms have substantial patient communities on Reddit and review aggregators like Trustpilot. Sentiment patterns are remarkably similar: people love the medication itself, get frustrated with customer service during high-demand periods, and wish pharmacy sourcing were more transparent.
Where they diverge: Henry Meds patients tend to speak more positively about the clinical relationship. Hims patients tend to emphasize price and speed. Neither community is shy about complaining when things go sideways.
How FormBlends fits into this comparison
FormBlends positions differently from both. The dispensing pharmacy is named up front, certificates of analysis are available on request, the clinical model involves synchronous review, and all-in pricing does not escalate with dose. FormBlends works with licensed 503A/503B compounding pharmacies.
The trade-off is that FormBlends is not the cheapest option, and there's no bundled coaching or lifestyle programming. Whether that combination makes sense depends on what the patient actually prioritizes.
So which one should you pick?
Hims makes more sense if:
- Starter price is your primary concern and you don't expect to stay on a high maintenance dose long-term
- You're comfortable with async-only clinical intake
- You want the option to switch to branded Zepbound through insurance later
- You want the fastest possible onboarding experience
Henry Meds makes more sense if:
- You want flat pricing through dose escalation
- Live video access to a clinician matters to you
- You're planning to stay on therapy for six months or longer
- You prefer a medication-focused program over a bundled wellness platform
Consider a third option if:
- You want structured coaching and dietitian access (look at Mochi Health, Lavender Sky Health)
- You want maximum pharmacy transparency (look at FormBlends or providers that name pharmacy partners up front)
- You have significant comorbidities and want synchronous clinical evaluation before anything ships
Frequently asked questions
Is Hims or Henry Meds cheaper for tirzepatide?
Hims is cheaper at the starter dose. Henry Meds can be cheaper at higher maintenance doses on a multi-month plan. The crossover depends on your specific dose escalation path and how long you stay on therapy.
Which has better clinical care?
Henry Meds offers more clinician contact through live video access. Hims runs primarily async. For healthy adults both are reasonable; for medically complex patients, Henry Meds's model is more conservative.
Can I get Zepbound (branded) at Henry Meds?
Henry Meds is primarily compounded-focused. Hims offers a branded Zepbound pathway through Lilly's direct programs.
Do either platform name their pharmacy?
Not on the marketing page. The dispensing pharmacy appears on the medication label. Patients can request more information through customer service at both platforms.
Have both been sued or investigated?
Both have drawn regulatory scrutiny in 2024 and 2025. Henry Meds has been named in Eli Lilly's compounded GLP-1 litigation. Hims has drawn congressional letters and trade-press coverage over marketing practices. Public records are searchable on PACER and the FDA warning letter database.
Which is faster to get started?
Hims's async intake is faster, sometimes same-day. Henry Meds's intake can take longer because of the live visit component.
Can I switch between them?
Yes. Patients have transitioned in both directions. Compounded tirzepatide from one platform is the same active ingredient as from another; the differences are in clinical model, pricing structure, and pharmacy sourcing.
Continue the series
- Hub: Best Tirzepatide Telehealth Providers 2026
- Detail: Hims Tirzepatide Review
- Detail: Henry Meds Tirzepatide Review
- Pillar: Compounded Tirzepatide Complete Guide
Important Safety Information
This article is for educational purposes only and is not medical advice. Compounded tirzepatide is not an FDA-approved drug. The FDA does not review compounded medications for safety, effectiveness, or quality before they are sold. Do not start, stop, or modify any prescription medication without speaking with a licensed healthcare provider. If you experience symptoms of a serious reaction, including severe abdominal pain, signs of pancreatitis, vision changes, persistent vomiting, signs of an allergic reaction, or thoughts of self-harm, seek emergency care immediately.
FormBlends is not a medical practice. FormBlends sells only compounded tirzepatide and compounded semaglutide through licensed U.S. pharmacies after a telehealth evaluation by an independent prescriber.
About this article
Written by Daniel Park, MS (Health Content Specialist). Medically reviewed by Dr. Anika Rao, MD (Board-Certified Internal Medicine). FormBlends content is reviewed by licensed U.S. clinicians prior to publication. Provider details are based on publicly available information as of early 2026 and may change. Always verify current pricing and program details on the provider's own site.
---
Not FDA-approved. Compounded medications are prepared by licensed pharmacies for individual patients based on a prescriber's clinical judgment. FormBlends is not a medical practice. Individual results vary. Consult a licensed clinician before starting any GLP-1 therapy.